CN117177770A - 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法 - Google Patents

使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法 Download PDF

Info

Publication number
CN117177770A
CN117177770A CN202280010805.7A CN202280010805A CN117177770A CN 117177770 A CN117177770 A CN 117177770A CN 202280010805 A CN202280010805 A CN 202280010805A CN 117177770 A CN117177770 A CN 117177770A
Authority
CN
China
Prior art keywords
cancer
tigit
antibody
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280010805.7A
Other languages
English (en)
Chinese (zh)
Inventor
张彤
薛柳
刘琦
魏旻
李康
左云霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beigene Ltd filed Critical Beigene Ltd
Publication of CN117177770A publication Critical patent/CN117177770A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280010805.7A 2021-01-21 2022-01-20 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法 Pending CN117177770A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
CN2021073083 2021-01-21
CNPCT/CN2021/073083 2021-01-21
CNPCT/CN2021/073308 2021-01-22
CN2021073308 2021-01-22
CN2021074141 2021-01-28
CNPCT/CN2021/074141 2021-01-28
CNPCT/CN2021/074644 2021-02-01
CN2021074644 2021-02-01
CNPCT/CN2021/075310 2021-02-04
CN2021075310 2021-02-04
CNPCT/CN2021/091822 2021-05-05
CN2021091822 2021-05-05
CN2021109322 2021-07-29
CNPCT/CN2021/109322 2021-07-29
PCT/CN2022/072869 WO2022156726A1 (en) 2021-01-21 2022-01-20 Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
CN117177770A true CN117177770A (zh) 2023-12-05

Family

ID=82548518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280010805.7A Pending CN117177770A (zh) 2021-01-21 2022-01-20 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法

Country Status (13)

Country Link
US (1) US20230391883A1 (https=)
EP (1) EP4281189A4 (https=)
JP (1) JP2024504331A (https=)
KR (1) KR20230158464A (https=)
CN (1) CN117177770A (https=)
AU (1) AU2022211109A1 (https=)
BR (1) BR112023014582A2 (https=)
CO (1) CO2023009626A2 (https=)
IL (1) IL304600A (https=)
MX (1) MX2023008597A (https=)
PE (1) PE20240659A1 (https=)
TW (1) TW202243691A (https=)
WO (1) WO2022156726A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242190A1 (zh) * 2024-05-24 2025-11-27 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115746144B (zh) * 2022-09-02 2026-01-02 安徽瀚海博兴生物技术有限公司 抗tigit-pd1双特异性抗体及其应用
WO2025002151A1 (zh) * 2023-06-27 2025-01-02 正大天晴药业集团股份有限公司 抗tigit抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016000853A2 (pt) * 2013-07-16 2017-12-12 Genentech Inc métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
TWI877769B (zh) * 2017-12-30 2025-03-21 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
KR102184377B1 (ko) * 2018-02-19 2020-11-30 고려대학교 산학협력단 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도
CN111836831A (zh) * 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
CN108840932B (zh) * 2018-04-28 2022-03-29 中国科学院微生物研究所 一种pd-1特异性抗体及其抗肿瘤应用
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN112618577B (zh) * 2020-12-15 2023-07-25 深圳君拓生物科技有限公司 动物双歧杆菌在提高肿瘤免疫治疗应答中的作用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242190A1 (zh) * 2024-05-24 2025-11-27 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤

Also Published As

Publication number Publication date
MX2023008597A (es) 2023-08-10
EP4281189A1 (en) 2023-11-29
JP2024504331A (ja) 2024-01-31
EP4281189A4 (en) 2025-01-08
AU2022211109A1 (en) 2023-09-07
BR112023014582A2 (pt) 2023-09-26
TW202243691A (zh) 2022-11-16
WO2022156726A1 (en) 2022-07-28
IL304600A (en) 2023-09-01
US20230391883A1 (en) 2023-12-07
KR20230158464A (ko) 2023-11-20
CO2023009626A2 (es) 2023-09-08
PE20240659A1 (es) 2024-04-04

Similar Documents

Publication Publication Date Title
KR102892725B1 (ko) 인간 넥틴4에 특이적인 항체
CN111526888B (zh) 抗tigit抗体及其作为治疗和诊断的用途
CN112566935B (zh) 抗ox40抗体和使用方法
CN108137691A (zh) 特异性针对人类t-细胞免疫球蛋白和itim结构域（tigit）的抗体
WO2022156726A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
WO2021098774A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2021098757A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
CA3205839A1 (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
CN114729047A (zh) 使用抗ox40抗体与化学治疗剂组合治疗癌症的方法
HK40103924A (zh) 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40076665A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40076664A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
HK40089230A (zh) 药物组合物及用途
HK40090273A (zh) 用於治疗癌症和感染的针对nkp46的抗体及其构建体
HK40074321B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
HK40076999A (en) Treatment of cancer with anti-ox40 antibodies and multi-kinase inhibitors
HK40060175B (zh) 特异性针对人类连接蛋白-2的抗体
HK40050839A (en) Anti-ox40 antibodies and methods of use
HK40060175A (en) Antibodies specific to human nectin-2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40103924

Country of ref document: HK